Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMX Immix Biopharma	$2.19	$2.52	$1.26 ▼ $3.20	$63.15M	0.28	163,996 shs	102,774 shs
OSTX OS Therapies	$2.19 +1.9%	$1.80	$1.12 ▼ $7.00	$69.26M	N/A	728,520 shs	556,076 shs
QNTM Quantum Biopharma	$18.14 +0.6%	$22.59	$2.70 ▼ $38.25	$52.79M	0.71	1.22 million shs	99,966 shs
XFOR X4 Pharmaceuticals	$2.80 -4.4%	$2.04	$1.35 ▼ $26.83	$16.21M	0.6	1.65 million shs	1.73 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMX Immix Biopharma	-4.78%	-4.78%	-26.26%	+4.78%	+4.78%
OSTX OS Therapies	-1.38%	+20.79%	+31.10%	+48.28%	-45.84%
QNTM Quantum Biopharma	-12.52%	-25.89%	-22.85%	+46.59%	+1,802,999,900.00%
XFOR X4 Pharmaceuticals	+17.67%	+13.79%	+104.90%	+5.78%	-86.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMX Immix Biopharma	3.2236 of 5 stars	3.5	5.0	0.0	0.0	0.6	3.3	0.6
OSTX OS Therapies	2.2387 of 5 stars	3.7	0.0	0.0	0.0	2.2	0.8	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	4.1199 of 5 stars	3.5	2.0	0.0	4.6	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMX Immix Biopharma	3.00	Buy	$7.00	219.63% Upside
OSTX OS Therapies	3.40	Buy	$18.00	721.92% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	3.00	Buy	$71.17	2,441.67% Upside

Current Analyst Ratings Breakdown

Latest XFOR, IMMX, QNTM, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/13/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $3.50
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.16 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A
XFOR X4 Pharmaceuticals	$2.56M	6.33	N/A	N/A	$0.69 per share	4.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMX Immix Biopharma	-$21.61M	-$0.77	N/A	N/A	N/A	N/A	-205.35%	-110.63%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
QNTM Quantum Biopharma	-$14.20M	-$14.02	N/A	N/A	N/A	N/A	-270.22%	-131.87%	N/A
XFOR X4 Pharmaceuticals	-$37.45M	-$14.84	N/A	N/A	N/A	-311.15%	-375.31%	-72.87%	N/A

Latest XFOR, IMMX, QNTM, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	-$0.22	-$0.01	-$0.22	N/A	N/A
8/8/2025	Q2 2025	XFOR X4 Pharmaceuticals	-$4.53	-$3.47	+$1.06	-$3.47	$1.62 million	$1.97 million
8/6/2025	Q2 2025	QNTM Quantum Biopharma	-$0.17	-$3.23	-$3.06	-$3.23	$2.89 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMX Immix Biopharma	N/A	1.23	1.23
OSTX OS Therapies	N/A	0.76	0.76
QNTM Quantum Biopharma	N/A	0.78	0.77
XFOR X4 Pharmaceuticals	19.10	3.19	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMX Immix Biopharma	11.26%
OSTX OS Therapies	N/A
QNTM Quantum Biopharma	1.24%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
IMMX Immix Biopharma	55.40%
OSTX OS Therapies	13.80%
QNTM Quantum Biopharma	8.53%
XFOR X4 Pharmaceuticals	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMX Immix Biopharma	9	28.83 million	12.86 million	Optionable
OSTX OS Therapies	N/A	31.62 million	N/A	N/A
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A
XFOR X4 Pharmaceuticals	80	5.79 million	5.67 million	Optionable

XFOR, IMMX, QNTM, and OSTX Headlines

Recent News About These Companies

Q3 EPS Forecast for X4 Pharmaceuticals Lifted by Analyst

August 17 at 2:04 AM | americanbankingnews.com

X4 Pharmaceuticals Grants Inducement Equity Awards to New Executive Officers

August 15, 2025 | quiverquant.comQ

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | globenewswire.com

X4 Pharmaceuticals Closes $85M Private Placement Deal

August 14, 2025 | theglobeandmail.com

X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright

August 13, 2025 | msn.com

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

August 13, 2025 | msn.com

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

August 13, 2025 | globenewswire.com

X4 Pharmaceuticals announces $60M financing, management changes

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60M Equity Financing

August 12, 2025 | msn.com

X4 Pharmaceuticals secures $60M PIPE financing

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

August 12, 2025 | globenewswire.com

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

X4 Pharmaceuticals Inc News (XFOR) - Investing.com

July 2, 2025 | investing.com

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR, IMMX, QNTM, and OSTX Company Descriptions

Immix Biopharma NASDAQ:IMMX

$2.19 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.19 0.00 (0.00%)

As of 04:10 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

OS Therapies NYSE:OSTX

$2.19 +0.04 (+1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$2.23 +0.04 (+1.83%)

As of 04:54 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Quantum Biopharma NASDAQ:QNTM

$18.14 +0.11 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$18.25 +0.11 (+0.61%)

As of 04:55 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

X4 Pharmaceuticals NASDAQ:XFOR

$2.80 -0.13 (-4.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.89 +0.09 (+3.21%)

As of 04:58 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time